Arcus Biosciences (RCUS) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
11 Jun, 2026Opening remarks and agenda
Meeting called to order at 8:30 A.M. with board members and executive team present.
Stockholders welcomed and informed of procedures for submitting questions.
Notice of meeting and stockholder list confirmed as distributed and available.
Board and executive committee updates
Attendance included all board members, key executives, and company auditors.
Shareholder proposals
Three proposals presented: election of directors, ratification of auditors, and advisory approval of executive compensation.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Arcus Biosciences
- Casdatifan and quemliclustat drive strong clinical and market prospects with pivotal data ahead.RCUS
Goldman Sachs 47th Annual Global Healthcare Conference 20269 Jun 2026 - Casdatifan and quemliclustat drive pipeline growth as Q1 net loss widens to $128M.RCUSQ1 202611 May 2026
- Virtual meeting to vote on directors, auditor, and executive pay, with strong governance and Gilead ties.RCUSProxy filing21 Apr 2026
- Votes will be held on director elections, auditor ratification, and executive pay approval.RCUSProxy filing21 Apr 2026
- Casdatifan and quemliclustat drive late-stage pipeline toward major 2026 milestones and markets.RCUS44th Annual J.P. Morgan Healthcare Conference12 Apr 2026
- Casdatifan achieved 45% ORR and 15.1-month PFS in RCC, with $1B cash supporting pipeline growth.RCUSQ4 20258 Apr 2026
- Casdatifan delivers higher efficacy and durable responses in RCC, with strong upcoming trial data.RCUSLeerink Global Healthcare Conference 20269 Mar 2026
- Phase III studies advance in gastric and RCC, with pivotal data and market expansion expected soon.RCUSGoldman Sachs 45th Annual Global Healthcare Conference1 Feb 2026
- Q2 revenue rose to $39M, $1.0B cash funds late-stage oncology trials into 2027.RCUSQ2 20241 Feb 2026